Please assess the completion status of the following clinical trial:

Trial Title: Aqueous Humor Dynamics and Brimonidine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be 19 years of age or older~* Subjects must exhibit a history of untreated IOPs between 21 and 35 mmHg (inclusive)~Exclusion Criteria:~* Age less than nineteen years old~* Women who are pregnant, lactating or of childbearing potential who are not using birth control measures.~* Aphakia or pseudophakia~* Best corrected visual acuity worse than 20/60 in either eye~* Chronic or recurrent severe ocular inflammatory disease~* Ocular infection or inflammation within (3) months of screening visit.~* History of clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy or retinal detachment.~* Any abnormality preventing reliable tonometry of either eye.~* Previous exposure to: beta-adrenergic antagonists, topical prostaglandin analogues within six (6) weeks of the baseline visit; α-adrenergic agonists within two (2) weeks of the baseline visit; and cholinergic agonists and carbonic anhydrase inhibitors within five (5) days of the treatment initiation visit.~* History of any severe ocular pathology (including severe dry eye) that would prelude the administration of a topical beta blocker, carbonic anhydrase inhibitor, or a topical prostaglandin.~* Any eye with a cup-to-disc ratio greater than 0.8.~* History of intraocular surgery~* History of ocular laser surgery~* History of severe or serious hypersensitivity to brimonidine or its vehicle.~* History of severe, unstable, or uncontrolled cardiovascular, hepatic or renal disease.~* History of bronchial asthma or chronic obstructive pulmonary disease (COPD).~* Less than one month (prior to baseline) stable dosing regimen of any non-glaucoma medication that would affect IOP.~* Gonioscopy angle \< 2.~* Inability to be dosed with treatment medication~* Inability to discontinue contact lens wear.~* Therapy with any investigational agent within 30 days of screening.~* Use of any additional topical or systemic adjunctive ocular hypotensive medications during the study.~* History of open angle glaucoma (either primary open angle glaucoma or other cause of open angle glaucoma) or narrow angle glaucoma.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intraocular pressure lowering drug (Type: ACTIVE_COMPARATOR): Eyedrops for lowering intraocular pressure
- Artificial Tears (Type: PLACEBO_COMPARATOR): Lubricated eye drops

Based on this trial design, predict the completion outcome and termination type (if applicable).